The aim of the research is to design a controller which administers cancer specific drug and thereby
The Research Field – Medical & Engineering Interdisciplinary Research
- The aim of antiangiogenic therapy is to stop the angiogenesis process (i.e. vascular system development) of the tumor; hence, to stop tumor growth
- Modern robust control algorithms provides automated drug administration
The Research Concept – Present & Future
- In the present clinical practice there are general protocols f
or cancer therapies (like chemotherapy, radiotherapy)
- these treatments have frequent and serious side effects
- they are not cancer specific and not personalized for the patients
- the treatment cost is low; however the usage is non-optimized
- Our concept: controller-based individualized treatment
- these treatments have virtually no side effect
- it provides personalized administration of cancer specific (antiangiogenic) drugs
- the treatment cost is duly low due to the optimal drug administration
Objectives of the Research – Model Identification & Controller Design
- Create mathematical tumor growth model under angiogenic inhibition based on animal experiments
- Create constant and variable quasi-continuous low-dosage therapy protocol
- Design optimal robust control algorithms for continuous low-dosage therapy
Impact of the Research – Opening New Horizons in Cancer Treatment
- Improve cancer therapy efficiency
- Decrease treatment costs
- Minimize side effects of the therapy
- Improve the patient's quality of life (QoL)
The Research Group
- Principal Investigator: Prof. Dr. Levente Kovács (Physiological Controls Group, Obuda University, Budapest, Hungary, Web: http://physcon.uni-obuda.hu/, Email: [email protected])
- 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
Szeretnéd, hogy a(z) iskolaod elsőként szerepeljen az Iskola tematikájú vállalkozások között Budapest városában?
